Statistical analysis for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Chi-squared test was used to analyze categorical data, ANOVA was used to analyze log-transformed antibody titers, and Wilcoxon rank-sum test was used for non-normally distributed data. Pairwise comparisons and estimates of differences between groups were done when difference between groups were significant. Possible effects of immunogenicity and safety profile of vaccine candidates were determined using multivariable analysis.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Study design and participants for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Procedures for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Statistical analysis for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial